Free Trial

LENSAR (LNSR) Competitors

LENSAR logo
$8.32 -0.25 (-2.92%)
As of 01/17/2025 04:00 PM Eastern

LNSR vs. CVRX, NPCE, SMTI, LUNG, DRTS, ELMD, ZYXI, INGN, NYXH, and RCEL

Should you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include CVRx (CVRX), NeuroPace (NPCE), Sanara MedTech (SMTI), Pulmonx (LUNG), Alpha Tau Medical (DRTS), Electromed (ELMD), Zynex (ZYXI), Inogen (INGN), Nyxoah (NYXH), and AVITA Medical (RCEL). These companies are all part of the "medical equipment" industry.

LENSAR vs.

CVRx (NASDAQ:CVRX) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, CVRx had 20 more articles in the media than LENSAR. MarketBeat recorded 20 mentions for CVRx and 0 mentions for LENSAR. CVRx's average media sentiment score of 0.64 beat LENSAR's score of 0.00 indicating that CVRx is being referred to more favorably in the media.

Company Overall Sentiment
CVRx Positive
LENSAR Neutral

CVRx presently has a consensus price target of $17.00, suggesting a potential downside of 3.52%. LENSAR has a consensus price target of $8.00, suggesting a potential downside of 3.85%. Given CVRx's higher possible upside, research analysts clearly believe CVRx is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CVRx
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
LENSAR
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

LENSAR has a net margin of -34.03% compared to CVRx's net margin of -123.75%. LENSAR's return on equity of -49.02% beat CVRx's return on equity.

Company Net Margins Return on Equity Return on Assets
CVRx-123.75% -89.06% -52.56%
LENSAR -34.03%-49.02%-21.12%

CVRx received 26 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 72.09% of users gave CVRx an outperform vote while only 38.46% of users gave LENSAR an outperform vote.

CompanyUnderperformOutperform
CVRxOutperform Votes
31
72.09%
Underperform Votes
12
27.91%
LENSAROutperform Votes
5
38.46%
Underperform Votes
8
61.54%

CVRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

LENSAR has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CVRx$39.29M10.88-$41.20M-$2.70-6.53
LENSAR$42.16M2.29-$14.38M-$1.46-5.70

75.3% of CVRx shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CVRx and LENSAR tied by winning 9 of the 18 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNSR vs. The Competition

MetricLENSARSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$96.60M$4.71B$5.21B$9.14B
Dividend YieldN/A47.30%5.13%4.02%
P/E Ratio-5.7026.2989.4217.36
Price / Sales2.2958.291,240.0477.11
Price / CashN/A50.1443.7535.97
Price / Book2.807.795.314.79
Net Income-$14.38M$13.87M$122.54M$225.00M
7 Day Performance8.62%2.85%1.42%2.37%
1 Month Performance8.05%10.48%2.51%4.40%
1 Year Performance133.05%32.32%25.29%20.10%

LENSAR Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNSR
LENSAR
0.8331 of 5 stars
$8.32
-2.9%
$8.00
-3.8%
+133.1%$96.60M$42.16M-5.70110
CVRX
CVRx
1.9407 of 5 stars
$15.04
+6.1%
$16.67
+10.8%
-33.6%$364.93M$47.26M-5.57160News Coverage
Positive News
NPCE
NeuroPace
3.5325 of 5 stars
$12.11
+1.4%
$15.00
+23.9%
-16.2%$361.46M$76.45M-12.11170
SMTI
Sanara MedTech
2.087 of 5 stars
$32.46
+0.7%
$47.00
+44.8%
-11.5%$283.73M$78.06M-32.7960
LUNG
Pulmonx
2.2144 of 5 stars
$7.05
+4.3%
$12.75
+80.9%
-51.9%$278.39M$79.30M-4.80250Positive News
DRTS
Alpha Tau Medical
2.4878 of 5 stars
$3.70
+14.6%
$8.00
+116.2%
+28.2%$258.72MN/A-8.6080Short Interest ↑
ELMD
Electromed
N/A$30.47
+2.4%
N/A+216.9%$257.72M$57.06M42.32160News Coverage
Positive News
ZYXI
Zynex
3.233 of 5 stars
$7.77
-0.8%
$14.00
+80.2%
-24.9%$247.44M$193.67M51.801,100Positive News
INGN
Inogen
3.3558 of 5 stars
$10.33
+8.2%
$7.00
-32.2%
+95.7%$246.04M$331.52M-4.591,030Short Interest ↓
Positive News
NYXH
Nyxoah
2.7765 of 5 stars
$9.33
+0.9%
$17.00
+82.2%
+142.2%$232.69M$5.08M-4.99110News Coverage
Positive News
RCEL
AVITA Medical
1.9536 of 5 stars
$8.82
-3.5%
$18.00
+104.1%
-37.8%$231.24M$60.04M-3.96130

Related Companies and Tools


This page (NASDAQ:LNSR) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners